Hemispherx BioPharma (HEB) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Hemispherx BioPharma (NYSEAMERICAN:HEB) issued its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.04, Fidelity Earnings reports.

NYSEAMERICAN:HEB opened at $0.16 on Tuesday. Hemispherx BioPharma has a twelve month low of $0.15 and a twelve month high of $0.50.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2019/04/02/hemispherx-biopharma-heb-releases-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Further Reading: What is a Fiduciary?

Earnings History for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.